Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 工程类 土木工程 政治学 法学
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜的应助被科研通管家采纳,获得10
刚刚
唠叨的觅海完成签到,获得积分10
1秒前
所所的应助被www采纳,获得10
4秒前
明朝发布了新的文献求助10
5秒前
科研小白的应助被化学废材采纳,获得10
7秒前
大个的应助被简单的夜绿采纳,获得10
8秒前
梁海萍完成签到,获得积分10
8秒前
HJK745完成签到,获得积分10
9秒前
9秒前
向阳而生完成签到,获得积分10
10秒前
10秒前
北梁的应助被如意语芹采纳,获得10
11秒前
12秒前
12秒前
张洁铃完成签到,获得积分10
14秒前
Vivian完成签到,获得积分10
14秒前
文献小当家完成签到,获得积分10
14秒前
Wsn完成签到,获得积分10
14秒前
wcli发布了新的文献求助10
14秒前
15秒前
16秒前
ding的应助被李嘉图采纳,获得10
17秒前
杨杨发布了新的文献求助10
18秒前
19秒前
cornelialkx发布了新的文献求助10
20秒前
赘婿的应助被JIM采纳,获得10
20秒前
22秒前
共享精神的应助被奋斗的灵松采纳,获得10
22秒前
爆米花的应助被hml123采纳,获得10
23秒前
24秒前
kkkay发布了新的文献求助10
25秒前
我是乐乐乐乐完成签到,获得积分10
26秒前
26秒前
ioi完成签到 ,获得积分10
27秒前
27秒前
29秒前
禾婉婉完成签到 ,获得积分10
29秒前
科研通AI6.4的应助被wangdongy采纳,获得10
29秒前
自然诗槐发布了新的文献求助10
29秒前
科目三的应助被9iiie采纳,获得10
30秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Composite Materials Handbook Volume 1 - Revision H 1500
Rosenblum, Global Change Biology 800
Computational Chemical Reaction Engineering: Modeling, Simulation, and Design with MATLAB 600
Organizational Behavior 510
Management and the Arts 510
Decentring Leadership 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7807980
求助须知:如何正确求助?哪些是违规求助? 9340501
关于积分的说明 20501908
捐赠科研通 7400094
什么是DOI,文献DOI怎么找? 3328529
关于科研通互助平台的介绍 2475415
邀请新用户注册赠送积分活动 2346879